METHOD FOR COMBINED TREATMENT OF NEOVASCULAR ANGLE-CLOSURE GLAUCOMA WITH UNDERLYING DIABETIC OR POST-THROMBOTIC MACULAR EDEMA IN PATIENTS WITH RESIDUAL VISION Russian patent published in 2024 - IPC A61F9/00 A61F9/07 A61F9/08 A61B3/00 

FIELD: medicine; ophthalmology.

SUBSTANCE: method involves combined treatment of neovascular angle-closure glaucoma with underlying diabetic or post-thrombotic macular edema in patients with residual vision. Diagnostic ophthalmologic examination is performed by optical coherence tomography to detect macular edema, its location and height. If observing neovascularization of the iris and/or in the angle of the anterior chamber, as well as parameters of increased intraocular pressure, treatment is carried out, the first step involves the introduction of a VHGF inhibitor by injection into a projection of a flat part of the ciliary body at 3.5–4.0 mm from the limb through a two-stage self-sealing puncture of the sclera into the vitreous body. Intraocular pressure is measured after 2 weeks and if observing its increased values, the second stage of treatment is performed—transscleral cyclophotocoagulation of the ciliary body. Then, 2–3 weeks later, panretinal laser coagulation of retina is performed in ischemic areas, and results of treatment are assessed 2 months after completion of treatment. One month after the second stage of treatment—transscleral cyclophotocoagulation of the ciliary body before panretinal laser coagulation of the retina in ischemic zones, intraocular pressure value is determined, and if its increased values are detected, an additional stage is performed—antiglaucoma operation with implantation of an Ahmed valve.

EFFECT: method enables to normalize intraocular pressure, has no effect on the ciliary body, does not reduce the production of aqueous humor, has a low risk of developing corneal complications and subatrophy of the eyeball, preserves residual visual functions and reduces risk of intra- and postoperative complications.

1 cl, 1 ex